课题基金 / 基金详情

ACTG300 COMBINED ZIDOVUDINE LAMIVUDINE VS BETTER OF DDI MONOTHERAPY V

ACTG300 COMBINED ZIDOVUDINE LAMIVUDINE VS BETTER OF DDI MONOTHERAPY V
ACTG300 联合齐多夫定 拉米夫定 VS 更好的 DDI 单疗法 V
批准号：
6264907
负责人：
MARGARET A KELLER
金额：
$0.1万
依托单位：
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6264907
关键词：
2'3' dideoxyinosine AIDS therapy HIV infections clinical research combination chemotherapy communicable disease control drug adverse effect drug screening /evaluation female human pregnant subject human subject human therapy evaluation lamivudine vertical transmission zidovudine

项目摘要

项目成果

MARGARET A KELLER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To determine the safety, tolerance and effectiveness of treatment with 3TC and ZDV, versus ddI versus ddI and ZDV when given to HIV-infected pregnant women and their babies. To see if taking these combinations of medications will further reduce the risk of HIV infections to the baby.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
INTENSIVE PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL DRUG COMBINATIONS HIV
INTENSIVE PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL DRUG COMBINATIONS
Two-Dimensional 3 Tesla MRS of the Brain in HIV- Infected Youth
PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL THERAPY DURING PREGNANCY
海外基金